No Data
Be Wary Of Sansure Biotech (SHSE:688289) And Its Returns On Capital
CICC Starts Sansure Biotech at Outperform With 25.90 Yuan Price Target
Sansure Biotech Inc. (688289.SH): Granted 1.2412 million restricted stocks to 56 incentive recipients.
On December 16th, Gelonghui reports that Sansure Biotech Inc. (688289.SH) announced that on December 16, 2024, it will hold the second Board of Directors' tenth temporary meeting and the second Supervisory Board's seventh temporary meeting in 2024. The meeting will review and approve the proposal regarding the granting of reserved restricted stocks to the incentive targets of the second phase of the 2023 restricted stock incentive plan, establishing December 16, 2024, as the reserved grant date, with a grant price of 8.55 yuan per share for 1.2412 million shares to 56 incentive targets.
Sansure Biotech Inc.'s (SHSE:688289) Most Bullish Insider, CEO Lizhong Dai Must Be Pleased With the Recent 8.0% Gain
Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.
①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.
Sansure Biotech Inc. (688289.SH) added Fengxia Yu and Fengying Long as core technical personnel.
Sansure Biotech Inc. (688289.SH) announced that the company's director, deputy general manager, and core technical staff member Fan Xu, along with core technology...
